Key facts
- This page summarizes Shane Barton's Form 4 filing for BioAge Labs, Inc. (BIOA).
- 18 reported transactions and 8 derivative rows are listed below.
- Accepted by SEC: 01 Jul 2026, 16:27.
Shane Barton - 29 Jun 2026 Form 4 Insider Report for BioAge Labs, Inc. (BIOA)
- Reporting relationship
- Principal Accounting Officer
- Issuer ticker
- BIOA
- Reported as of
- 29 Jun 2026
- Net transaction value
- -$1,576,752
- SEC form
- 4
- Accepted by SEC
- 01 Jul 2026, 16:27:06 UTC
- Prior SEC filing
- 19 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Dov A. Goldstein as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Shane Barton filed Form 4 for BioAge Labs, Inc. (BIOA) on 01 Jul 2026.
Change
- Previous filing in this sequence was filed on 19 Feb 2026.
- Current net transaction value: -$1,576,752.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001836297
Primary reporting owner
Barton Shane
- Relationship
- Principal Accounting Officer
- Address
- C/O BIOAGE LABS, INC., 5885 HOLLIS STREET, SUITE 370, EMERYVILLE
- Signature
- /s/ Dov A. Goldstein as attorney-in-fact
- Signature date
- 01 Jul 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BIOA
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +9,301
- Change %
- +353%
- Price
- $10.85*
- Shares after
- 11,933
- Date
- 29 Jun 2026
- Ownership
- Direct
- Footnotes
- F1
BIOA
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +7,261
- Change %
- +61%
- Price
- $8.39*
- Shares after
- 19,194
- Date
- 29 Jun 2026
- Ownership
- Direct
- Footnotes
- F1
BIOA
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +8,958
- Change %
- +47%
- Price
- $4.30*
- Shares after
- 28,152
- Date
- 29 Jun 2026
- Ownership
- Direct
- Footnotes
- F1
BIOA
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +14,198
- Change %
- +50%
- Price
- $4.38*
- Shares after
- 42,350
- Date
- 29 Jun 2026
- Ownership
- Direct
- Footnotes
- F1
BIOA
transaction
Common Stock
Sale
- Transaction value
- $1,067,576
- Shares
- -42,350
- Change %
- -100%
- Price
- $25.21
- Shares after
- 0
- Date
- 29 Jun 2026
- Ownership
- Direct
- Footnotes
- F1, F2
BIOA
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +4,290
- Change %
- Price
- $10.85*
- Shares after
- 4,290
- Date
- 30 Jun 2026
- Ownership
- Direct
- Footnotes
- F1
BIOA
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +4,000
- Change %
- +93%
- Price
- $8.39*
- Shares after
- 8,290
- Date
- 30 Jun 2026
- Ownership
- Direct
- Footnotes
- F1
BIOA
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +4,065
- Change %
- +49%
- Price
- $4.30*
- Shares after
- 12,355
- Date
- 30 Jun 2026
- Ownership
- Direct
- Footnotes
- F1
BIOA
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +7,861
- Change %
- +64%
- Price
- $4.38*
- Shares after
- 20,216
- Date
- 30 Jun 2026
- Ownership
- Direct
- Footnotes
- F1
BIOA
transaction
Common Stock
Sale
- Transaction value
- $509,176
- Shares
- -20,216
- Change %
- -100%
- Price
- $25.19
- Shares after
- 0
- Date
- 30 Jun 2026
- Ownership
- Direct
- Footnotes
- F1, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BIOA
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -9,301
- Change %
- -35%
- Price
- $0.000000*
- Shares after
- 17,589
- Date
- 29 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,301
- Exercise price
- $10.85
- Footnotes
- F1, F4
BIOA
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -7,261
- Change %
- -26%
- Price
- $0.000000*
- Shares after
- 21,016
- Date
- 29 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,261
- Exercise price
- $8.39
- Footnotes
- F1, F5
BIOA
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -8,958
- Change %
- -22%
- Price
- $0.000000*
- Shares after
- 31,042
- Date
- 29 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 8,958
- Exercise price
- $4.30
- Footnotes
- F1, F6
BIOA
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -14,198
- Change %
- -16%
- Price
- $0.000000*
- Shares after
- 75,802
- Date
- 29 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 14,198
- Exercise price
- $4.38
- Footnotes
- F1, F7
BIOA
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -4,290
- Change %
- -24%
- Price
- $0.000000*
- Shares after
- 13,299
- Date
- 30 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,290
- Exercise price
- $10.85
- Footnotes
- F1, F4
BIOA
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -4,000
- Change %
- -19%
- Price
- $0.000000*
- Shares after
- 17,016
- Date
- 30 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,000
- Exercise price
- $8.39
- Footnotes
- F1, F5
BIOA
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -4,065
- Change %
- -13%
- Price
- $0.000000*
- Shares after
- 26,977
- Date
- 30 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,065
- Exercise price
- $4.30
- Footnotes
- F1, F6
BIOA
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -7,861
- Change %
- -10%
- Price
- $0.000000*
- Shares after
- 67,941
- Date
- 30 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,861
- Exercise price
- $4.38
- Footnotes
- F1, F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 7 footnotes
Footnote F1
The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025.
Footnote F2
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.79 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
Footnote F3
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.42 per share, inclusive.
Footnote F4
The option vested as to 1/4th of the total award on September 25, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Footnote F5
The option vested as to 1/4th of the total award on October 17, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Footnote F6
The option vested as to 1/4th of the total award on October 26, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Footnote F7
The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.